

## ASX Announcement (ASX: HLS)

ASX Limited  
Market Announcements Office  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000



ACN 064 530 516  
REGISTERED OFFICE:  
Level 22  
161 Castlereagh Street  
SYDNEY NSW 2000  
TEL: +61 2 9432 9400

25 June 2024

### Healius announces Trading Update for FY 2024

Healius Limited (ASX: HLS) today announced a trading update for FY 2024 and now expects:

- Underlying FY 2024 Earnings Before Interest Tax and Depreciation (EBITDA) of between \$345 million - \$350 million; and
- Underlying FY 2024 Earnings Before Interest and Tax (EBIT) of between \$60 million - \$65 million.

Improving Pathology volumes for the half year to date have been offset by lower than expected average fees due to the softer GP market, and general inflationary pressures. Pathology volumes for January to May have increased by 3.9% on pcp.

The transformation program for Pathology is well underway and the company expects to marginally exceed the \$15m targeted net savings for FY24.

Lumus Imaging and Agilex Biolabs have continued to perform well and in line with company expectations.

**ENDS**

The release of this announcement has been authorised by the Board.

For further information contact:

#### **Analysts and Market**

Sharon Ng  
Investor Relations  
Mobile: +61 466 023 858

*For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,500 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.*